Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating centhaquine citrate LYFAQUIN1, a novel drug being studied as a resuscitative agent for adults with hypovolemic shock, which is a life-threatening condition caused by severe blood or fluid loss. This phase IV, open-label, multi-center study aims to assess the safety and efficacy of centhaquine when added to the standard shock treatment. Centhaquine acts on specific receptors to improve blood flow and reduce vascular resistance, with prior studies showing promising effects on blood pressure, lactate levels, cardiac output, and mortality in animal models. Participants aged 18 years or older with hypovolemic shock and low systolic blood pressure 90 mmHg or lower will receive centhaquine intravenously at a dose of 0.01 mgkg body weight over one hour, in addition to standard care such as fluid resuscitation and vasopressors. A second dose may be given if blood pressure remains low, with no more than three doses in 24 hours and treatment continuing up to two days after enrollment. Each patient will receive between one and six doses within the first 48 hours. Throughout hospitalization, participants will be monitored closely until discharge or up to seven days after joining the trial. Researchers will assess safety by tracking adverse events and efficacy by measuring blood pressure, lactate levels, base deficit, ICU stay duration, ventilator use, urine output, mortality, organ dysfunction scores, respiratory distress, and neurological status. Statistical analyses will compare patient outcomes to understand centhaquines effects as an addition to standard hypovolemic shock treatment.
Actively Recruiting
Researchers are evaluating the use of antiplatelet therapy, specifically Aspirin 75 mg daily, to prevent major adverse cardiovascular and cerebrovascular events MACE in patients who have survived intracerebral haemorrhage ICH. This Phase 3, randomized, placebo-controlled, triple-blinded clinical trial plans to recruit 5676 patients aged 18 to 99 years across 50 stroke centers in India. The study aims to address the safety and effectiveness of starting antiplatelet monotherapy after ICH, a question not yet resolved by large trials. Participants will be randomly assigned to receive either daily Aspirin 75 mg or a matching placebo, both alongside standard secondary prevention care. The medication and follow-up duration depend on recruitment timing those recruited in the first year will take the medication for up to three years or until an event occurs, while those recruited later will take it for a minimum of six months with matching follow-up. The total trial duration is three years, with recruitment lasting 2.5 years and follow-up continuing until the study ends. The investigational products are centrally manufactured and dispensed yearly at each site. Participants will undergo face-to-face visits every three months to receive the medication and return unused tablets, with monthly phone calls to monitor adherence and detect any events. Brain imaging by CT or MRI will be done as part of routine care at baseline and if events occur. Researchers will collect clinical data, medication adherence, and functional assessments such as the modified Rankin Scale. Safety monitoring includes event adjudication and follow-up until three years or until withdrawal, death, or event occurrence. The primary outcome is the occurrence of MACE over three years.